PL1890684T3 - Leczenie zaburzeń snu i czuwania - Google Patents

Leczenie zaburzeń snu i czuwania

Info

Publication number
PL1890684T3
PL1890684T3 PL06772647T PL06772647T PL1890684T3 PL 1890684 T3 PL1890684 T3 PL 1890684T3 PL 06772647 T PL06772647 T PL 06772647T PL 06772647 T PL06772647 T PL 06772647T PL 1890684 T3 PL1890684 T3 PL 1890684T3
Authority
PL
Poland
Prior art keywords
sleep
treatment
wake disorders
wake
disorders
Prior art date
Application number
PL06772647T
Other languages
English (en)
Polish (pl)
Inventor
Abdallah Ahnaou
Wilhelmus H I M Drinkenburg
Joseph Palumbo
Jonathan Sporn
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1890684(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of PL1890684T3 publication Critical patent/PL1890684T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06772647T 2005-06-08 2006-06-07 Leczenie zaburzeń snu i czuwania PL1890684T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
EP06772647.1A EP1890684B1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (1)

Publication Number Publication Date
PL1890684T3 true PL1890684T3 (pl) 2014-05-30

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06772647T PL1890684T3 (pl) 2005-06-08 2006-06-07 Leczenie zaburzeń snu i czuwania

Country Status (17)

Country Link
US (8) US8440715B2 (enExample)
EP (1) EP1890684B1 (enExample)
JP (1) JP5024635B2 (enExample)
KR (1) KR101335941B1 (enExample)
CN (1) CN101217949B (enExample)
AU (1) AU2006254899B2 (enExample)
BE (1) BE2020C004I2 (enExample)
BR (1) BRPI0613697A2 (enExample)
CA (1) CA2611713C (enExample)
DK (1) DK1890684T3 (enExample)
ES (1) ES2435403T3 (enExample)
FR (1) FR20C1014I2 (enExample)
NL (1) NL301037I2 (enExample)
PL (1) PL1890684T3 (enExample)
RU (1) RU2417077C2 (enExample)
TW (2) TWI419681B (enExample)
WO (1) WO2006133393A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217949B (zh) 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
CA2612672C (en) * 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
CN106727486A (zh) * 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
RU2557533C2 (ru) * 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
CA2779457C (en) * 2009-11-06 2017-10-17 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
MX381381B (es) * 2013-03-13 2025-03-12 Sk Biopharmaceuticals Co Ltd Tratamiento de cataplejía mediante compuestos de carbamato
US9226910B2 (en) 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
WO2016061488A1 (en) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY197630A (en) 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
JP7366002B2 (ja) * 2017-07-31 2023-10-20 ジャズ ファーマシューティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール類縁体およびその使用
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
EP4615426A1 (en) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DK0873308T3 (da) * 1996-10-10 2002-04-22 Sk Corp O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
PL364638A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
US7078436B2 (en) * 2001-02-27 2006-07-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating anxiety disorders
US6589985B2 (en) * 2001-02-27 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating movement disorders
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
CN101217949B (zh) 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
CN101272776B (zh) 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
BRPI0719275A2 (pt) 2006-10-13 2014-04-29 Janssen Pharmaceutica Nv Composições de carbamatos de fenil-alquil-amino
CN106727486A (zh) 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
CA2779457C (en) 2009-11-06 2017-10-17 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
MX381381B (es) * 2013-03-13 2025-03-12 Sk Biopharmaceuticals Co Ltd Tratamiento de cataplejía mediante compuestos de carbamato

Also Published As

Publication number Publication date
TW201328689A (zh) 2013-07-16
JP5024635B2 (ja) 2012-09-12
US20090312416A1 (en) 2009-12-17
NL301037I1 (enExample) 2020-04-01
US20210078943A1 (en) 2021-03-18
KR101335941B1 (ko) 2013-12-04
US9604917B2 (en) 2017-03-28
US20140350098A1 (en) 2014-11-27
CA2611713A1 (en) 2006-12-14
JP2008545795A (ja) 2008-12-18
US20240239740A1 (en) 2024-07-18
BE2020C004I2 (enExample) 2026-01-06
AU2006254899A1 (en) 2006-12-14
ES2435403T3 (es) 2013-12-19
US20170158622A1 (en) 2017-06-08
BRPI0613697A2 (pt) 2011-01-25
DK1890684T3 (da) 2013-10-14
NL301037I2 (nl) 2020-05-12
AU2006254899B2 (en) 2011-11-24
CN101217949B (zh) 2012-10-17
EP1890684B1 (en) 2013-08-14
RU2008100019A (ru) 2009-07-20
FR20C1014I2 (fr) 2021-04-23
US8877806B2 (en) 2014-11-04
CA2611713C (en) 2013-10-01
US20190367448A1 (en) 2019-12-05
WO2006133393A1 (en) 2006-12-14
US20130137764A1 (en) 2013-05-30
US11753368B2 (en) 2023-09-12
TWI419681B (zh) 2013-12-21
US10351517B2 (en) 2019-07-16
US12209059B2 (en) 2025-01-28
TW200716084A (en) 2007-05-01
EP1890684A1 (en) 2008-02-27
FR20C1014I1 (enExample) 2020-06-12
KR20080035565A (ko) 2008-04-23
RU2417077C2 (ru) 2011-04-27
CN101217949A (zh) 2008-07-09
US8440715B2 (en) 2013-05-14
US20250109099A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
PL1890684T3 (pl) Leczenie zaburzeń snu i czuwania
IL185052A0 (en) Treatment of bone disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
IL186408A0 (en) Combination treatment methods
IL194189A0 (en) Combination treatment of metabolic disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
GB0605715D0 (en) Treatment of laminitis
GB0426196D0 (en) Methods of treatment
GB0515035D0 (en) Treatment of atherosclerotic conditions
ZA200708853B (en) Methods of treatment utilizing certain melatonin derivatives
GB0518003D0 (en) Treatment of hepatatis c
GB0602857D0 (en) The treatment of sialorrhoea
GB0512757D0 (en) Treatment of respiratory disorders
HU0400952D0 (en) Treatment of anus-cancer
GB0511322D0 (en) Treatment of rail
GB0509298D0 (en) Treatment of inflammation
GB0619218D0 (en) Treatment of conformational disorders
GB2445888B (en) Treatment of hypertension
TJ20050863A (en) The way of narcotism treatment